First-Line Nivolumab Shows Significant Promise for Patients with cSCC
https://unsplash.com/photos/G6wVoIJY-iI

First-Line Nivolumab Shows Significant Promise for Patients with cSCC

Both Libtayo (cemiplimab) and Keytruda (pembrolizumab) have been shown to be beneficial treatment options for patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC). But could Opdivo (nivolumab)…

Continue Reading First-Line Nivolumab Shows Significant Promise for Patients with cSCC
INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)
Photo courtesy of Amolyt Pharma

INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)

When it comes to drug development and medical research, particularly within the rare disease sphere, it is incredibly important for patients to feel involved in the process. After all, patients…

Continue Reading INTERVIEW: Dr. Mark Sumeray Discusses Positive Phase 2a Data on AZP-3601 for Hypoparathyroidism (Pt. 1)